As of 4:00pm ET
| -0.18 / -3.01%|
The 3 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 14.00, with a high estimate of 15.00 and a low estimate of 12.50. The median estimate represents a +140.96% increase from the last price of 5.81.
The current consensus among 4 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.